BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20039313)

  • 1. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors.
    Jensen ED; Pham L; Billington CJ; Espe K; Carlson AE; Westendorf JJ; Petryk A; Gopalakrishnan R; Mansky K
    J Cell Biochem; 2010 Mar; 109(4):672-82. PubMed ID: 20039313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation.
    Pham L; Beyer K; Jensen ED; Rodriguez JS; Davydova J; Yamamoto M; Petryk A; Gopalakrishnan R; Mansky KC
    J Cell Biochem; 2011 Mar; 112(3):793-803. PubMed ID: 21328453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
    Okamoto M; Murai J; Yoshikawa H; Tsumaki N
    J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
    Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
    Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2.
    Usui M; Xing L; Drissi H; Zuscik M; O'Keefe R; Chen D; Boyce BF
    J Bone Miner Res; 2008 Mar; 23(3):314-25. PubMed ID: 17967138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin A receptor type 1-mediated BMP signaling regulates RANKL-induced osteoclastogenesis via canonical SMAD-signaling pathway.
    Omi M; Kaartinen V; Mishina Y
    J Biol Chem; 2019 Nov; 294(47):17818-17836. PubMed ID: 31619522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient mice through increased BMP signaling.
    Sotillo Rodriguez JE; Mansky KC; Jensen ED; Carlson AE; Schwarz T; Pham L; MacKenzie B; Prasad H; Rohrer MD; Petryk A; Gopalakrishnan R
    J Bone Miner Res; 2009 Nov; 24(11):1917-26. PubMed ID: 19419314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis.
    Broege A; Pham L; Jensen ED; Emery A; Huang TH; Stemig M; Beppu H; Petryk A; O'Connor M; Mansky K; Gopalakrishnan R
    J Biol Chem; 2013 Dec; 288(52):37230-40. PubMed ID: 24235143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous regucalcin stimulates osteoclastogenesis and suppresses osteoblastogenesis through NF-κB activation.
    Yamaguchi M; Weitzmann MN; Murata T
    Mol Cell Biochem; 2012 Jan; 359(1-2):193-203. PubMed ID: 21842421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
    Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
    Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.
    Enomoto H; Shiojiri S; Hoshi K; Furuichi T; Fukuyama R; Yoshida CA; Kanatani N; Nakamura R; Mizuno A; Zanma A; Yano K; Yasuda H; Higashio K; Takada K; Komori T
    J Biol Chem; 2003 Jun; 278(26):23971-7. PubMed ID: 12697767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between IL-6 and soluble IL-6 receptor enhances bone morphogenetic protein-2/absorbable collagen sponge-induced bone regeneration via regulation of BMPRIA distribution and degradation.
    Huang RL; Chen G; Wang W; Herller T; Xie Y; Gu B; Li Q
    Biomaterials; 2015 Oct; 67():308-22. PubMed ID: 26232880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.